Hormone replacement therapy (HRT) in women with premature ovarian insufficiency

Abstract:

Premature ovarian insufficiency (POI) is a clinical syndrome defined by the loss of ovarian activity before the age of 40. It is manifested by menstrual cycle disorder along with elevated gonadotrophin values. Hormone replacement therapy (HRT) is indicated for the treatment of symptoms as well as for the risk of low estrogen. Women should be informed that HRT can play a role in preventing cardiovascular diseases and preserving bone density. Patients should be aware that it has not been found to increase the risk of breast cancer before the age of natural menopause. 17β-estradiol is a preferred estrogen replacement. Women should be informed of the micronized natural progesterone advantages and that oral cyclic combined treatment represents the most powerful endometrial protection. It is necessary to take into account the patient’s preferences regarding the route and the mode of administration of each HRT component.

Key words:
hormone replacement therapy; premature ovarian insufficiency